Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 7Breast Neoplasms 4Peripheral Nervous System Diseases 2Squamous Cell Carcinoma of Head and Neck 1Radiodermatitis 1Primary Ovarian Insufficiency 1Ototoxicity 1Neurotoxicity Syndromes 1Nervous System Diseases 1Mucositis 1Insulin Resistance 1Infertility, Female 1Infertility 1Hyperandrogenism 1Head and Neck Neoplasms 1Disease Progression 1Cisplatin Nephrotoxicity 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Female 1

Interventions

sodium thiosulfate 4Cisplatin 4Methotrexate 2Chemotherapy, Adjuvant 2Acetylcysteine 2tempol 1ebselen 1Vorinostat 1Vincristine 1Thioctic Acid 1Surveys and Questionnaires 1Sodium Chloride 1Restraint, Physical 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiotherapy 1Radiosurgery 1Pantoprazole 1Mental Status and Dementia Tests 1Magnetic Resonance Spectroscopy 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Hyaluronic Acid 1Hearing Tests 1Genetic Association Studies 1Drug Therapy 1Dexamethasone 1Cyclophosphamide 1Chemoradiotherapy 1Carboplatin 1Audiometry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ototoxicity × Thioctic Acid × Clear all
NCT00477607 2014-03-07

Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin

VA Office of Research and Development

Phase 2/3 Completed
39 enrolled 11 charts

Ototoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡